AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6509875
Drug: Heparin 10
RxNorm normalized name: heparin 10 units/mL injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 10 units/ml in 0.9% sodium chloride injection
Trial: 6509875
Drug: Heparin 100
RxNorm normalized name: heparin 100 units/mL injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 100 units/ml in 0.9% sodium chloride injection
Trial: 28371815
Drug: FG-4592 low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FG-4592 low-dose (1.1-1.75 mg/kg)
Trial: 28371815
Drug: FG-4592 high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FG-4592 high-dose (1.50-2.25 mg/kg)
Trial: 28371815
Drug: FG-4592 low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FG-4592 low-dose (1.1-1.8 mg/kg)
Trial: 28371815
Drug: FG-4592 medium-dose
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FG-4592 medium-dose (1.5-2.3 mg/kg)
Trial: 28371815
Drug: FG-4592 high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FG-4592 high-dose (1.7-2.3 mg/kg)
Trial: 28371815
Drug: FG-4592 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FG-4592 (all doses)
Trial: 28371815
Drug: FG-4592 high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FG-4592 high-dose
Trial: 21511749
Drug: ICRU point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICRU point doses in Group A (n=50)
Trial: 16918716
Drug: L-arginine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (3 g daily)
Trial: 11605012
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (including anthracycline and non-anthracycline based regimens)
Trial: 9469687
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (Atrovent) nebulizer solution with BAC and EDTA
Trial: 9469687
Drug: Albuterol nebulizer
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol nebulizer solution with BAC
Trial: 9469687
Drug: EDTA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA in nebulizer solutions
Trial: 9469687
Drug: Preservative-free bronchodilator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free bronchodilator nebulizer solutions
Trial: 125068
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 1.5% aqueous solution of 6-aminonicotinamide for four weeks
Trial: 24895097
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy indicated by current guidelines
Trial: 23937923
Drug: 10mg intravenous
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg intravenous dexamethasone intraoperatively
Trial: 23937923
Drug: 24-hour postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-hour postoperative dose of 10mg intravenous dexamethasone
Trial: 18650033
Drug: Open label
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label sustained-release bupropion (300 mg/day) with gain-framed messages
Trial: 18650033
Drug: Open label
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label sustained-release bupropion (300 mg/day) with loss-framed messages
Trial: 16858180
Drug: Iloprost (intra-arterial,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost (intra-arterial, intraoperative bolus of 3000 ng, plus intravenous infusion of 0.5-2.0 ng/kg/min for 6 hours/day for 4-7 days following surgery)
Trial: 12460133
Drug: 9-session cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-session cognitive behavioral treatment (CBT) with motivational enhancement therapy (MET) and case management (CM) components
Trial: 2024858
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (high-dose steroid therapy plus cyclophosphamide therapy for 8 weeks)
Trial: 2024858
Drug: Plasmapheresis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmapheresis treatment (12 plasmapheresis procedures during the first 4 weeks)
Trial: 6724070
Drug: Liquid nitrogen
DrugBank: Nitrogen (DB09152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid nitrogen (subsequent treatment)
Trial: 30962877
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus manual therapy (5 sessions, 30 min each)
Trial: 30962877
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus manual therapy
Trial: 26755593
Drug: MF59-adjuvanted trivalent
RxNorm normalized name: Influenza, adjuvanted, trivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted trivalent inactivated influenza vaccine (ATIV)
Trial: 23774008
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for childhood OCD, 12-session course
Trial: 23774008
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for childhood OCD
Trial: 22926289
Drug: Naftopidil 25
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Naftopidil 25 mg/day
Trial: 22926289
Drug: Naftopidil 25
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Naftopidil 25 mg/day plus tolterodine 2 mg (twice a day)
Trial: 10521751
Drug: Morning meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning meal administered at 7 AM after a fast of ≥5 hours
Trial: 10521751
Drug: Evening meal
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening meal administered at 9 PM after a fast of ≥5 hours
Trial: 31022892
Drug: Iron folate
RxNorm normalized name: Iron Folate-F
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron folate group (60 mg elemental iron and folate)
Trial: 31022892
Drug: Folate group
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate group (2.5 mg of folate)
Trial: 26914455
Drug: Veratric acid
RxNorm normalized name: veratrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veratric acid (VA) cream applied topically; specific dosage and duration not mentioned.
Trial: 22706571
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron sucrose co-administered with IV Vitamin C (IS + C)
Trial: 20130877
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and cisplatin (75 mg/m2 every 3 weeks)
Trial: 20130877
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and cisplatin with radiation therapy (RT; 45 Gy)
Trial: 18040014
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) at a mean dose of 2000 mg/day
Trial: 18040014
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) at a mean dose of 564 mg/day
Trial: 18040014
Drug: Non-drug
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug
Trial: 15656813
Drug: Once-daily use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily use of topical corticosteroids
Trial: 15656813
Drug: More frequent
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More frequent use of topical corticosteroids
Trial: 15656813
Drug: Twice-daily treatment
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily treatment with potent topical corticosteroids
Trial: 15656813
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times daily use of very potent topical corticosteroids
Trial: 7491877
Drug: Dexfenfluramine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine (30 mg)
Trial: 6809627
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Trial: 6809627
Drug: 25 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Trial: 6809627
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Trial: 6809627
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Trial: 31571526
Drug: Dynamic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic treatment regimen for increasing motivation to attend treatments
Trial: 26291817
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg intravaginal progesterone
Trial: 26291817
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg intravaginal progesterone
Trial: 21836549
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving weekly encouragement to remain smoke free and routine breastfeeding support.
Trial: 21162922
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection of ropivacaine, morphine and epinephrine
Trial: 17923867
Drug: Intensive CEP
RxNorm normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive CEP (C 1800 mg m(‐2), E 50 mg m(‐2), P 75 mg m(‐2) with filgrastim 5 mug kg(‐1) per day x 10 days)
Trial: 17923867
Drug: Standard CEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CEP (C 500 mg m(‐2), E 50 mg m(‐2), P 75 mg m(‐2))
Trial: 29706210
Drug: Amoxicillin (antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (antibiotic prophylaxis)
Trial: 20177681
Drug: 4,000 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4,000 IU/day low molecular weight heparin (LMWH) prophylaxis
Trial: 12935823
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T levels >0.1 microg/L
Trial: 12935823
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T levels <=0.1 microg/L
Trial: 12935823
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T cutoff value 0.03 microg/L
Trial: 12935823
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T cutoff value 0.01 microg/L
Trial: 12935823
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T cutoff value <=0.01 microg/L
Trial: 10673519
Drug: G-CSF (filgrastim)
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (filgrastim) administered at a daily dose of 5 microg/kg after two courses of intensive consolidation chemotherapy (ICC)
Trial: 8790153
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits (Duraflo II) and reduced systemic heparinization (ACT > 250s)
Trial: 8790153
Drug: Non-coated circuits
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-coated circuits and standard heparin administration (ACT > 480s)
Trial: 7969680
Drug: 3H‐ANG(1‐8) infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3H‐ANG(1‐8) infusion (0.5, 2.0, and 2.5 ng/kg/min)
Trial: 3593628
Drug: Ibopamine administered
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine administered immediately after a meal
Trial: 3593628
Drug: Ibopamine administered
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine administered 2 hours after a meal
Trial: 3593628
Drug: Ibopamine administered
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine administered 0.5 hours before a meal
Trial: 3593628
Drug: Ibopamine administered
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine administered 3 hours after a meal
Trial: 3593628
Drug: Ibopamine administered
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine administered in fasting state
Trial: 21957976
Drug: Telmisartan-based plus
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan-based plus simvastatin therapy
Trial: 21957976
Drug: Telmisartan-based monotherapy
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan-based monotherapy
Trial: 16680067
Drug: E2/NETA (17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/NETA (17beta‐estradiol 2 mg plus norethisterone acetate 1 mg)
Trial: 16680067
Drug: Low E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low E2/NETA (17beta‐estradiol 1 mg plus norethisterone acetate 0.5 mg)
Trial: 1799474
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b 5 million units subcutaneously three times weekly until progression or relapse
Trial: 6656960
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (radiotherapy with chemotherapy: methotrexate and 5-fluorouracil)
Trial: 6656960
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (radiotherapy with chemotherapy)
Trial: 28648704
Drug: Bicruciate-stabilized implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicruciate-stabilized implant
Trial: 28648704
Drug: Posterior-stabilized implant
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior-stabilized implant
Trial: 25889509
Drug: Selenium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (200 μg/d L-selenomethionine)
Trial: 17726586
Drug: Intra-articular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular ketamine (0.25 mg S-(+)-ketamine/kg body weight in 10 ml 0.9% NaCl)
Trial: 17726586
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.25 mg S-(+)-ketamine/kg body weight)
Trial: 17726586
Drug: Intra-articular bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular bupivacaine (10 ml 0.25% bupivacaine)
Trial: 17726586
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 ml 0.9% NaCl)
Trial: 9562230
Drug: Sertindole 20
RxNorm normalized name: sertindole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole 20 mg daily
Trial: 7651057
Drug: N-acetylcysteïne (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteïne (NAC) 3 x 600 mg per day for 5 days, starting 5 or 10 days after Photofrin
Trial: 2689182
Drug: Diltiazem (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (360 mg per day orally)
Trial: 2689182
Drug: Methotrexate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (4 g.m-2 body surface area)
Trial: 766724
Drug: Laxogas gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxogas gas producing suppositories
Trial: 31917843
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg IV every 3 weeks for up to 8 cycles, starting within 21 days of post-ASCT discharge)
Trial: 24699943
Drug: Integrated and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated and culturally attuned CBT group treatment (n = 18)
Trial: 10969346
Drug: Genotypic guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotypic guided treatment
Trial: 9428983
Drug: Biapenem 500
RxNorm normalized name: biapenem
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem 500 mg administered intravenously over 30 min
Trial: 9428983
Drug: Biapenem administered
RxNorm normalized name: biapenem
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem administered after haemodialysis or in double the dose on haemodialysis days
Trial: 7679869
Drug: Benazepril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (20 mg) and Hydrochlorothiazide (50 mg) for 3 months
Trial: 7679869
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg) for 3 months
Trial: 29194772
Drug: Aspirin 1
RxNorm normalized name: aspirin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1 mg/kg
Trial: 29194772
Drug: Clopidogrel 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 2 mg/kg
Trial: 29194772
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Aspirin + Clopidogrel)
Trial: 23424159
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA) 20 mg daily
Trial: 27473139
Drug: Interferon β-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon β-1b (IFN‐β‐1b) 250 μg subcutaneous every other day
Trial: 19815651
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (70 mg/m² on days 1, 8, and 15) combined with carboplatin (AUC = 6 on day 1)
Trial: 19815651
Drug: Standard paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard paclitaxel (200 mg/m² on day 1) combined with carboplatin (AUC = 6 on day 1)
Trial: 19101902
Drug: Triamcinolone 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone 1% ointment
Trial: 19101902
Drug: Water-based gel
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-based gel (control)
Trial: 10084064
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low molecular weight heparin (OP 2000)
Trial: 7486089
Drug: Epinephrine 7.5
RxNorm normalized name: bupivacaine HCl/epinephrine 7.5 mg/mL (0.75 %)-1:200,000 INJECTION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 7.5 group (3 mL 1.5% lidocaine containing 7.5 micrograms epinephrine)
Trial: 7486089
Drug: Epinephrine 15
RxNorm normalized name: lidocaine HCl/epinephrine 15 mg/mL (1.5 %)-1:200,000 INJECTION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 15 group (3 mL 1.5% lidocaine containing 15 micrograms epinephrine)
Trial: 7486089
Drug: Epinephrine 22.5
RxNorm normalized name: epinephrine 22.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 22.5 group (3 mL 1.5% lidocaine containing 22.5 micrograms epinephrine)
Trial: 7486089
Drug: Saline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline group (3 mL normal saline)
Trial: 399436
Drug: Coccinia indica
RxNorm normalized name: COCCINIA INDICA FRUIT EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coccinia indica preparation (experimental group)
Trial: 27327849
Drug: Gum chewing
RxNorm normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum chewing (sugar-free gum every 2 hours for 20 minutes from the end of drinking 2 L of PEG to the beginning of colonoscopy)
Trial: 27327849
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 L of PEG before colonoscopy)
Trial: 23677743
Drug: Finely crushed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finely crushed ORF tablets
Trial: 23677743
Drug: Coarsely crushed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coarsely crushed ORF tablets